Omapatrilat for the management of heart failure and hypertension

Husereau D R

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Husereau D R. Omapatrilat for the management of heart failure and hypertension. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 4

Authors' objectives
To summarise the available evidence on the use of omapatrilat for the management of heart failure and hypertension.

Authors' conclusions
- Omapatrilat, first in a new class of cardiovascular drugs called vasopeptidase inhibitors, is under evaluation for the management of hypertension and heart failure.

- Several small trials have demonstrated the efficacy and tolerability of once-daily omapatrilat in the treatment of mild to moderate hypertension. Efficacy data from one medium-sized trial have demonstrated a benefit comparable to lisinopril in the treatment of systolic heart failure.

- The benefits and risks of omapatrilat as compared to ACE inhibitors are under evaluation and could affect future clinical therapy guidelines for managing hypertension and heart failure.

Project page URL
https://www.ccohta.ca/research/index.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Heart Diseases /drug therapy; Hypertension /drug therapy

Language Published
English, French

Country of organisation
Canada

Address for correspondence
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392; Email: jills@ccohta.ca.

AccessionNumber
32001000955

Date bibliographic record published
31/08/2001
Date abstract record published
31/08/2001